Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Androgen Receptor
24%
Ataxia Telangiectasia
8%
Biological Marker
72%
Brain Cancer
9%
Breast Cancer
20%
Cancer
23%
Cancer Cell
31%
Cancer Stem Cell
9%
Cancer Surgery
18%
Circulating Tumor Cell
97%
Clear Cell Renal Cell Carcinoma
36%
Clinical Trial
11%
Clinician
12%
Colorectal Carcinoma
48%
Disease
10%
Disease Free Survival
28%
Diseases
13%
Epidermolysis Bullosa Dystrophica
9%
Exosome
10%
Glioblastoma
39%
Immunotherapy
18%
Liquid Biopsy
38%
Lymphocyte
22%
Malignant Neoplasm
64%
Melanoma Cell
24%
Mesenchymal-Epithelial Transition
11%
Metastatic Carcinoma
24%
Metastatic Colorectal Cancer
8%
microRNA
14%
Microsatellite Instability
9%
Multivariate Analysis
11%
Neoplasm
66%
Neutrophil
20%
Nivolumab
9%
Nucleic Acid
13%
Oncology
12%
Osimertinib
8%
Overall Survival
30%
Patient Referral
16%
Pembrolizumab
8%
Personalized Medicine
9%
Phytochemical
14%
Polo Like Kinase 1
16%
Programmed Death-Ligand 1
10%
Prostate Cancer
40%
Radiation Therapy
36%
Rectum Cancer
41%
Resveratrol
9%
Squamous Cell Carcinoma
16%
Treatment Response
10%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
24%
Adverse Event
21%
Androgen
25%
Androgen Receptor
25%
Biological Marker
67%
Breast Cancer
8%
Cancer Survival
16%
Carboplatin
10%
Castration Resistant Prostate Cancer
38%
Chemoradiation Therapy
29%
Chemotherapy
53%
Cisplatin
9%
Clinical Trial
12%
Colorectal Carcinoma
16%
Disease Free Survival
14%
Diseases
23%
Enzalutamide
9%
Fluorouracil
8%
Gemcitabine
16%
Glioblastoma
22%
Immunotherapy
11%
Kidney Metastasis
11%
Malignant Neoplasm
71%
Metastasis
9%
microRNA
11%
Neoplasm
100%
Nivolumab
9%
Overall Survival
48%
Oxaliplatin
8%
Pazopanib
26%
Pembrolizumab
8%
Pharmacokinetics
29%
Phospholipase
8%
Phytochemical
14%
Placebo
11%
Prednisone
28%
Prodrug
8%
Programmed Cell Death
16%
Progression Free Survival
25%
Prostate Cancer
63%
Randomized Clinical Trial
9%
Rectum Cancer
41%
Recurrent Disease
10%
Renal Cell Carcinoma
34%
Resveratrol
9%
Solid Malignant Neoplasm
17%
Sunitinib
18%
Thyroid Cancer
9%
Tumor Marker
9%
Tumor Regression
8%
Immunology and Microbiology
Ataxia Telangiectasia
8%
Autophagy
8%
Biological Activity
8%
Blood Sampling
8%
Body Fluid
8%
Cancer Cell
24%
Cancer Stem Cell
16%
Cancer Survival
13%
Carcinoma Cell
8%
Cell Death
11%
Cell Growth
16%
Cell Isolation
14%
Circulating Tumor Cell
66%
Colon
8%
Conatumumab
8%
Cryopreservation
8%
Cytokine Production
8%
Disease Free Survival
30%
DNA Damage Response
12%
Drug Therapy
8%
Epithelial Cell Adhesion Molecule
11%
Epithelial Mesenchymal Transition
41%
Exosome
8%
Gamma Urogastrone
8%
Immunity
8%
Immunotherapy
16%
Lycopene
8%
Melanoma Cell
8%
Microsatellite Instability
9%
Neural Cell Adhesion Molecule
8%
Nivolumab
9%
Overall Survival
24%
Pazopanib
8%
Pembrolizumab
9%
Programmed Cell Death 1
8%
Programmed Death-Ligand 1
18%
Progression Free Survival
9%
Prostate
32%
Prostate Cancer Cell Line
8%
Prostate Specific Antigen
8%
Protein Complex
8%
Radioresistance
13%
RNA Splicing
8%
Sensitive Detection
8%
Signal Transduction
8%
Squamous Cell
8%
Thyroid
16%
Tumor Cell
12%
Tumor Spheroid
8%
Untranslated Region
8%